Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

994211

registered interest
date	24/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the National Institute for Health and Care Excellence has to facilitate commercial discussions between manufacturers and NHS England at an early stage in its evaluations of highly specialised technologies.
tabling member constituency	Sheffield, Hallam
tabling member printed	Jared O'Mara
uin	183457
answer	answer is ministerial correction date of answer 01/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) it has recently set up a commercial function that specifically focuses on engaging in discussions around commercial arrangements - The Commercial and Managed Access Programme. Through this function, NICE will provide companies with opportunities to engage in commercial and managed access conversations with both NICE and NHS England.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/11/2018 16:46:48 answering member 4067 label Biography information for Steve Brine
tabling member	4661 label Biography information for Jared O'Mara

994212

registered interest
date	24/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Muscular Dystrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the introduction of a cost-effectiveness threshold in the NICE highly specialised technologies appraisal process, what steps he is taking to ensure equity of access to treatment for different subgroups of patients with Duchenne muscular dystrophy.
tabling member constituency	Sheffield, Hallam
tabling member printed	Jared O'Mara
uin	183458
answer	answer is ministerial correction date of answer 01/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) evaluates all medicines referred to its highly specialised technologies (HST) programme, including medicines for Duchenne muscular dystrophy, consistently in accordance with its published methods and processes. In 2017, following public consultation, NICE introduced an assessment of cost-effectiveness into its HST methodology that provides a consistent and transparent mechanism for evaluating technologies while recognising the need for greater flexibility in the evaluation of very high cost drugs for the treatment of very rare diseases.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/11/2018 16:39:13 answering member 4067 label Biography information for Steve Brine
tabling member	4661 label Biography information for Jared O'Mara